HER-2 Expression in Colorectal Cancer and Its Correlation with Immune Cell Infiltration.

This study aimed to investigate the effect of increased HER-2 expression on tumor-infiltrating lymphocytes (TILs) and determine its impact on the prognosis of colorectal cancer (CRC) patients; Methods: HER-2, CD4, CD8, CD19, LY6G, CD56, CD68, CD11b, and EpCam expression in CRC tissues and adjacent paracancerous tissues were assessed using multiplex fluorescence immunohistochemical staining. The correlation between HER-2 expression and the number of TILs in CRC tissues was analyzed. Kaplan-Meier and Cox proportional hazards models were used to analyze survival outcomes; Results: The expression of HER-2 in tumor tissues was higher than that in paracancerous tissues (1.31 ± 0.45 vs. 0.86 ± 0.20, < 0.05). Additionally, there was an increase in the numbers of CD4+, CD8+, CD19+, and CD68+ cells in CRC tissues (14.11 ± 1.10 vs. 3.40 ± 0.18, < 0.005; 0.16 ± 0.12 vs. 0.04 ± 0.04, < 0.005; 0.71 ± 0.46 vs. 0.25 ± 0.13, < 0.0005; 0.27 ± 0.24 vs. 0.03 ± 0.11, < 0.05). An increase in HER-2 expression was positively correlated with an increase in CD4, CD8, and CD19 ( < 0.0001). In HER-2-positive CRC tissues, CD68 expression was increased (0.80 ± 0.55 vs. 0.25 ± 0.22, < 0.05). In HER-2-upregulated CRC tissues, CD4, CD8, CD19, CD68, CD11b, Ly6G, and CD56 expressions were elevated (0.70 ± 0.37 vs. 0.32 ± 0.17, = 0.03; 0.22 ± 0.13 vs. 0.09 ± 0.06, = 0.03; 0.31 ± 0.19 vs. 0.12 ± 0.08, = 0.02; 1.05 ± 0.62 vs. 0.43 ± 0.21, < 0.01; 1.34 ± 0.81 vs. 0.53 ± 0.23, < 0.01; 0.50 ± 0.31 vs. 0.19 ± 0.10, < 0.01; 1.26 ± 0.74 vs. 0.52 ± 0.24, < 0.01). Furthermore, increased HER-2 expression was an independent risk factor for recurrence-free survival (RFS) in patients ( < 0.01, HR = 3.421); Conclusions: The increased expression of HER-2 and its relationship with immune cells will provide new insights for immunotherapy in CRC patients.